



Pharmaceutical systems and current developments

Olga Solomon, Head of DG SANTE Unit B5

"Health as the Real Winner : Presidency Conference on Options to Provide Better Medicines for All" - Sofia, 6 March 2018



European
Commission

OUTLINE

- Challenges and political context
- Optimisation of existing legal framework
- Review of the system



European
Commission

OUTLINE

- **Challenges and political context**
- Optimisation of existing legal framework
- Review of the system

Challenges (I)

Does the pharmaceutical framework ensure **balance** between

- Innovation
- Availability & patient access?





European
Commission

Challenges (II)

Council Conclusions June 2016

- The functioning of the pharmaceutical systems depends on **a delicate and complex set of interactions** between **marketing authorisation and measures to promote innovation**, the pharmaceutical market, and national approaches on pricing, reimbursement and assessment of medicinal products
- Further **analysis** to examine the current functioning of the pharmaceutical systems in the EU and Member States, **in particular in relation to the impact of certain incentives** in EU pharmaceutical legislation, **the use by economic operators** and the **consequences for the innovation, availability, accessibility and affordability** of medicinal products for the benefit of the patients (...)



European
Commission

Political context

- **1 December 2014:** Council Conclusions on innovation for the benefits of patients
- **17 June 2016:** Council Conclusions on strengthening the balance in the pharmaceutical systems
- **2 March 2017:** European Parliament Resolution on EU options for improving access to medicines



European
Commission

Council Conclusions of June 2016

23.7.2016

EN

Official Journal of the European Union

C 269/31

Council conclusions on strengthening the balance in the pharmaceutical systems in the European Union and its Member States

(2016/C 269/06)

<http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-balance-pharmaceutical-system/>




European
Commission

OUTLINE

- Challenges and political context
- **Optimisation of existing legal framework**
- Review of the system

Access to medicines - STAMP





European
Commission

Optimisation of existing tools

Main initiatives within STAMP – 2015-2017

Repurposing

**Early access
initiatives**

**Compassionate
use**

**Synergy with HTA
Network**

**Off-label
use**

Repurposing - Main challenges

- Regulatory framework
- Incentives
- Off-label use
- Data quality
- Cooperation between stakeholders
- Pricing





European
Commission

Repurposing - opportunities

- Underlying reasons for industry's reluctance to include new indications
- Improve knowledge of non-industry organisations and academics about the regulatory framework for the authorisation of medicines
- Mechanisms to provide advice or support on data quality
- Bring stakeholders together within a platform





European
Commission

OUTLINE

- Challenges and political context
- Optimisation of existing legal framework
- **Review of the system**

Analysing the impact of pharmaceutical incentives

"PAEDIATRICS STUDY"

- Economic evaluation of the impact of the Paediatric Regulation with focus on incentives and rewards.

Early 2016 - end 2017

SPC: "LEGAL STUDY"

- Study on legal aspects of the EU SPC framework.

Ongoing

PAEDIATRICS REPORT

- Report on the impact of the Paediatric Regulation from an economic and public Health Perspective.

October 2017

COMPLEMENTARY STUDY

- Study to cover some additional aspects of the pharmaceutical regulation if necessary.

2018

End 2017

SPC: "PRELIMINARY ECONOMIC STUDY"

- Study on different economic aspects surrounding SPC in Europe.

April 2017 - Q1 2018


"ECONOMIC STUDY": IMPACT OF PHARMA INCENTIVES AND SPC ON INNOVATION, AVAILABILITY AND ACCESSIBILITY OF MEDICINAL PRODUCTS

- Economic study on the impact of pharmaceutical incentives and rewards, including SPC, data/market protection and market exclusivity for orphans and paediatric rewards.



European
Commission

Evaluation





European
Commission

**T
I
M
E
L
I
N
E**

November 2017 - Roadmap

4-week public consultation

2018/2019 Study on orphans

Various stakeholders' consultations

2019

Evaluation

Supplementary Protection Certificates

- DG GROW is assessing **three aspects**:
 - the possibility of creating a "unitary" SPC title
 - an update of the scope of the EU patent Bolar and research exemptions
 - the introduction of an SPC manufacturing waiver.
- **Oct. 2017 - Jan. 2018**: 12-week on-line public consultation on SPC and patent research exemptions

Possible SPC manufacturing waiver

- **May 2016:** European Parliament Resolution:
'Urges the Commission to introduce and implement before 2019 an SPC manufacturing waiver'
- **Stakeholder consultation:** suggested that the SPC regime does not optimise the competitiveness of EU generic and biosimilar firms versus non-EU firms
- Various studies published and others nearing completion

Possible SPC waiver (II)

- Impact assessment work in view of a possible targeted initiative is currently ongoing
- No decision on a legislative proposal taken
- EU remains committed to pharmaceutical innovation via SPC protection (both at home and abroad)



Thank you !

More information:

http://ec.europa.eu/health/documents/pharmaceutical-committee/stamp/index_en.htm